Related Experiment Videos
[Seniors and cardiovascular medications]
H Matejovská Kubesová1, P Weber, H Meluzínová
1Klinika interní, geriatrie a praktického Iékarství Lékarské fakulty MU a FN Brno. hkubes@med.muni.cz
Vnitrni Lekarstvi
|July 15, 2011
Summary
Elderly cardiovascular disease treatment is challenging, particularly managing dyslipidemia. This review highlights risks of common cardiovascular drugs in older adults, including ACE inhibitors, antiplatelets, and beta-blockers.
Area of Science:
- Cardiology
- Geriatric Medicine
- Pharmacology
Context:
- Cardiovascular diseases (CVDs) pose significant challenges in elderly patients.
- Current therapeutic strategies, especially for dyslipidemia, require careful consideration in older populations.
- Polypharmacy and age-related physiological changes increase risks associated with CVD medications.
Purpose:
- To analyze the current therapeutic landscape for cardiovascular diseases in the elderly.
- To identify and discuss the specific risks and adverse effects of various cardiovascular medications in geriatric patients.
- To provide a comprehensive overview of drug-related complications in elderly CVD management.
Summary:
- The article reviews common cardiovascular medications, including angiotensin converting enzyme blockers, antiplatelets, anticoagulants, beta-blockers, calcium channel blockers, diuretics, and digoxin.
- Specific risks such as hyperkalemia with ACE inhibitors, gastrointestinal bleeding with antiplatelets/anticoagulants, bradycardia with beta-blockers, and drug interactions are detailed.
- A concluding table summarizes potential clinical symptoms of adverse effects for frequently used cardiovascular drugs in the elderly.
Impact:
- Enhances understanding of geriatric pharmacotherapy for cardiovascular conditions.
- Aids clinicians in optimizing medication selection and monitoring for elderly patients with CVD.
- Provides a practical resource for identifying and managing adverse drug events in this vulnerable population.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...